Candriam S.C.A. Sells 182,223 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Candriam S.C.A. cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 44.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 224,530 shares of the medical equipment provider's stock after selling 182,223 shares during the quarter. Candriam S.C.A. owned approximately 0.32% of Lantheus worth $18,027,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of LNTH. Vanguard Group Inc. boosted its holdings in Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock valued at $458,271,000 after purchasing an additional 389,828 shares during the period. Westfield Capital Management Co. LP increased its stake in Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock valued at $121,867,000 after acquiring an additional 394,837 shares during the period. Farallon Capital Management LLC raised its holdings in Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock valued at $92,316,000 after acquiring an additional 1,269,900 shares in the last quarter. Reinhart Partners LLC. lifted its position in shares of Lantheus by 8.4% in the 1st quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider's stock worth $91,517,000 after acquiring an additional 114,110 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Lantheus by 0.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 839,957 shares of the medical equipment provider's stock valued at $52,077,000 after purchasing an additional 7,590 shares during the period. Institutional investors own 99.06% of the company's stock.

Insider Transactions at Lantheus

In other news, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the company's stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now directly owns 98,980 shares of the company's stock, valued at $9,540,682.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the sale, the chief accounting officer now owns 62,557 shares in the company, valued at approximately $4,990,171.89. The disclosure for this sale can be found here. Insiders sold 41,193 shares of company stock valued at $3,949,202 over the last three months. Company insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on LNTH. JMP Securities dropped their price target on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research report on Thursday, August 1st. B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Truist Financial dropped their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Leerink Partners boosted their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. Finally, Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $126.00.

Lantheus Trading Down 3.2 %

Shares of NASDAQ LNTH traded down $3.36 during midday trading on Friday, reaching $101.98. 561,405 shares of the stock were exchanged, compared to its average volume of 1,036,350. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The company has a market capitalization of $7.07 billion, a price-to-earnings ratio of 15.57 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The business has a 50-day simple moving average of $102.61 and a two-hundred day simple moving average of $81.60.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. During the same quarter last year, the company earned $1.40 earnings per share. The firm's revenue was up 22.5% compared to the same quarter last year. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 6.03 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.